Questions That Often Come Up Before Starting People often want to know how quickly they will see results, whether the weight comes back after stopping, and how GLP-1 medications compare to other weight loss treatments
A 2025 meta-analysis in Diabetes, Obesity and Metabolism confirmed that across SURMOUNT-1 to -4, GI adverse events with tirzepatide ranged from 27.8% to 72.8% (any GI event) versus 12.2% to 32.5% on placebo, with discontinuation due to GI symptoms running 1.0% to 10.5%
4 However, data specific to postmenopausal women, who may have distinct vascular and metabolic profiles, remain limited
Currently, targeting ferroptosis can reverse chemotherapeutic resistance, which mainly consists of three pathways related to the ferroptosis mechanism, typically the GPX4-regulated pathway, the iron metabolism pathway, and the lipid metabolism pathway (42)
As a triple receptor agonist targeting GLP-1, GIP, and glucagon pathways simultaneously, it produced weight reduction numbers in clinical trials that made even seasoned researchers pause